Lyra Therapeutics reports Q1 net loss of $8.5M; ENLIGHTEN 2 top-line results expected Q2 2025

Lyra Therapeutics, Inc.

2025-Q1 EPS reported -$0.13 vs consensus -$6.97 ▲ beat (+98.1%)

Net loss of $8.5M ($0.13 per share) vs. $22.5M ($0.35) in Q1 2024; cash burn reduced YoY.
Cash & equivalents $31.7M at March 31, 2025, down from $40.6M at Dec 31, 2024.
Topline Phase 3 ENLIGHTEN 2 data for LYR-210 in CRS expected in Q2 2025; ~65 polyp patients across both ENLIGHTEN trials.
Plans a reverse stock split to comply with Nasdaq $1.00 minimum bid; stockholder vote on May 14, 2025.
R&D expenses fell to $4.9M from $18.2M YoY, driven by completion of BEACON and ENLIGHTEN 1 trials and May 2024 workforce reduction.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-25-064475
form_type: 8-K
ticker: LYRA
cik: 0001327273
company_name: Lyra Therapeutics, Inc.
filed_at: 2025-05-06T23:59:59+00:00
discovered_at: 2026-05-14T18:02:47.948374+00:00
generated_at: 2026-05-22T11:11:17.496618+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: negative
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-25-064475
json_url: https://secwatch.observer/filing/0000950170-25-064475.json
markdown_url: https://secwatch.observer/filing/0000950170-25-064475.md
text_url: https://secwatch.observer/filing/0000950170-25-064475.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1327273/000095017025064475/0000950170-25-064475-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1327273/000095017025064475/lyra-20250506.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0000950170-25-064475

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.